|
|
The Market for Tissue and Organ TransplantationPublished by: BCC Research Published: Mar. 1, 2003 - 300 Pages Table of ContentsIntroduction Study Goal And Objectives Reasons For Doing The Study Contributions Of The Study And For Whom Scope And Format Methodology Information Sources Author’s Credentials Related Bcc Publications Reports Monthly Newsletters Bcc On-Line Services Summary Organs Tissues Summary Table Us Organ And Tissue Transplantation Markets, Through 2007 Summary Figure Us Organ And Tissue Transplantation Markets, 2002 And 2007 ($ Millions) General Trends Overview Importance Of The Industry Organs Table 1 Us Organ Transplants, Average 1 St Year Cost And Market Totals, Through 2007 Kidney Liver Heart Lung Intestine Pancreas Waiting Lists Waiting Lists Grow Faster Than Numbers Of Transplantations International Trends Limited Supply Puts Breaks On Transplantations Table 2 Numbers Of Donated Cadavers By Region, 1997-2001 Tissues Aging Baby Boomers Driving Market Table 3 Tissue Grafting In The Us, Through 2007 (Number Of Procedures) Figure 1 Issue Grafting In The Us, 2002 - 2007 (Number Of Procedures) Cornea Blood Stem Cells Bone Allografts Heart Valves Vascular Tissue Skin And Collagen Larger Potential Markets, Same Limits On Supply Table 4 Potential And Expected Us Markets For Transplanted Human Tissue, Through 2007 ($ Millions) Table 4 (Continued) Widespread Distrust Of For-Profit Companies Could Retard Growth More Regulation Applications The Transplantation Process Preparation Operation Recuperation Maintenance Products In The Transplantation Process Hla Tissue Typing Organ Preservation Products Anti-Rejection Drugs Antibiotics Post-Transplant Monitoring Alternatives To Transplantation Government Regulation And Patents Evolution Of Transplantation Tissue Typing Immunosuppression Preservation Government Reimbursement Of Transplantation Costs Mechanical Organs General Trends Supply Management Reducing Waste And Rejection Increasing The Harvest Table 5 Recovered Organs Not Used, 1995-1999 Table 6 Consented Organs Not Recovered, 1995-1999 Better Harvesting Papworth Cocktail Remembering The Ultimate Customer, The Patient On The Waiting List Less Waste Preservation Rinse/Preservation Solutions Table 7 Major Organ Preservation Solutions Collins Solution Viaspan Celsior Custodiol Table 8 The North American And World Markets For Organ Preservation Solution (Except Papwork Cocktail), Through 2007 Market Size Potential New Alternatives Machine Perfusion Waters Medical Systems Bio-Preserve International Transmedics, Inc Non-Heart-Beating Donors Testing Blood Typing Tissue Typing Panel Reactive Antibodies (Pra) Table 9 Types Of Typing Advances Table 10 Players In The Hla Typing Market The Market For Histocompatibility Supplies And Services Table 11 The Us Market For Tissue Typing Services, Through 2007 ($ Million) Splitting The Market Regulation Plasmapheresis: Transplantation Without Matching Antigens Post-Transplant Biotronik Isis Data Sciences Reperfusion Injury Fighting Rejection Table 12 Number Of Patients In The Us Who Are On Waiting List Because Of Graft Failure (Failure Of Previously Transplanted Organ), All Organs, 1995-1999 Table 13 Percent Of Us Patients On Waiting List By Organ Who Had A Previous Transplant, 1995-1999 (%) Table 14 Us Organ Recipients Who Previously Had A Transplant, All Organs, 1995-1999 Immunosuppression Market Size Table 15 Worldwide Market For Immunosuppression, Through 2007 Table 16 Worldwide Sales Of Immunosuppressives By Company, 1999-2001 ($ Millions) Crowded Market Five Types Of Immunosuppressives Table 17 Us Sales Of Immunosuppressives By Type, Through 2007* ($ Millions) Figure 2 Us Sales Of Immunosuppressives By Type, 1999-2007 ($ Millions) Table 18 World Sales Of Immunosuppressive By Type, Through 2007 ($ Million Antiproliferatives Calcineurin Inhibitors Calcineurin Inhibitors (Continued) Antibodies Tor Inhibitors Table 19 Experimental Immunosuppressives By Type Clinical Testing Generics Governors, Corporate Executives Want To Let Generics Compete Sooner Governors, Corporate Executives Want To Let Generics Compete Sooner (Continued) Effect Of Shorter Monopoly Times On Transplantation Drug Research State Prosecutors Target Drug Makers International Patent Rights Trips Impact Of Waste Reduction On Supply Transplantation Without Rejection Tolerance Antisense Therapy Costimulation Chimerism University Of Pittsburgh Massachusetts General Hospital And Biotransplant Abgenix Chimeric Therapies Insurance Fighting Infections Table 20 Common Post-Transplant Infections Table 21 Common Post-Transplant Drugs Table 21 (Continued) Table 22 Cost Of Transplant Antibiotics In The Us, Through 2007 ($ Millions) Monitoring Table 23 The World Market For Transplant Drug And Disease Monitoring Agents, Through 2007 ($ Millions) The Efficiency Dividend Table 24 Maximum Potential For Additional Organs Compared To Demand In The Us, 1999 Tissue Finding More Supply Expanding Traditional Sources: Getting More Cadavers Spain Sets Donation Standard Table 25 International Organ Donor Rates, 2000 (Per Million Of Population) Even With Increased Donation, Waiting Lists Persist Table 26 Transplantations And Waiting List Numbers In Spain, 2000 Reforms To Boost Donation Presumed Consent Table 27 Selected Countries And Type Of Consent Donor Compensation Tapping New Sources: Expanding Donation To New Nations And Living Donors Shifting Cadaveric Donation Table 28 Countries With Kidney Transplant Programs Table 28 (Continued) The Argentinean Collapse Table 29 Kidney, Liver, Heart Transplants By Region, 2000 Table 29 (Continued) More Competition Splinters Market Organ Selling Meets Dammed Up Demand Marketing Availability Belgium And Austria Costa Rica South Africa Pakistan Cuba Tissues Effects Of Globalization Living Donors Table 30 Trends In Living And Cadaveric Donation In The Us Through 2007 Kidney Exchanges Reimbursement For Costs New Technologies Organs From Animals: Xenotransplantation Overcoming Hyperacute Rejection Porcine Endogenous Retrovirus Major Competitors Political Problems Artificial Organs Reducing Demand Cellular Transplants The Challenge Of Aging Populations Table 31 Growth Of Selected Population Groups In The Us, Through 2007 (Millions) Organs Kidneys Table 32 Number Of Kidney Transplantations By Region, Through 2007 Table 33 The Us Kidney Transplant Market, Through 2007 ($ Millions) Figure 3 The Us Kidney Transplant Market, 2002-2007 ($ Millions) Table 34 The Top Four Kidney Transplant Programs In The Us, 2000 (By Number Of Procedures) Table 35 Kidney Patient And Graft Survival, Us (%) Table 36 Costs Per Year Due To End Stage Renal Disease, 1995-1999 Transplantation Too Rare To Be A Solution Table 37 Waiting List Trends By Region, Through 2007 Shortage Is Worse In Japan Cadaveric Donations Falling Table 38 Number Of Kidney Transplantations In The Us From Living And Cadaveric Donors, Through 2007 Table 39 Kidney Transplantation In Norway From Living And Cadaveric Donors, Through 2007 Closing The Kidney Gap Indications Table 40 Leading Causes Of Kidney Failure (%) Table 41 Leading Causes Of Kidney Transplantation (%) International Trends Older Recipients Less Rejection Table 42 Hazard Ratio For Graft Failure (1993 = 1) Immunosuppression Table 43 Estimated Us Market For Immunosuppressives For Kidney Transplant Patients, Through 2007 Advances Chimerism Alternatives Mechanical Medical Animal Cellular Pancreas Table 44 Growth Of Whole Pancreas Transplantation, Through 2007 Table 45 Us Whole Pancreas Transplantation Market, Through 2007 ($ Millions) Figure 4 Us Whole Pancreas Transplantation Market, 2000-2007 ($ Millions) Table 46 The Top Four Pancreas Transplant Programs In The Us, 2000 (Number Of Transplants) Islet Cells Table 47 International And Us Pancreas Graft Survival Rates (%) A Breakthrough Juvenile Diabetes Research Foundation Drawbacks Table 48 Pancreas Waiting List, Us, Through 2007 Immunosuppression Controversy Indications Alternatives Cell Encapsulation Biohybrid Technologies Circe Biomedical Islet Technologies Cultured Stem Cells Medical Nuerochem Columbia University Costs Liver Numbers Table 49 Growth In Liver Transplants By Region, Through 2007 Table 50 Liver Transplant Market In The Us, Through 2007 ($ Millions) Figure 5 Liver Transplant Market In The Us, 2000-2007 ($ Millions) Table 51 The Top Four Liver Transplant Programs In The Us, 2000 Donors Table 52 Trends In Living Donor Liver Transplants In The Us Waiting List Table 53 Growth In Liver Waiting Lists By Region, Through 2007 Table 54 Deaths On Liver Waiting List, Us, Through 2007 Indications Causes Of Cirrhosis Tissue Typing Organ Recovery Rejection Table 55 Liver Transplant Survival Rates* (%) Table 56 The Us Market For Immunosuppressants After Liver Transplantation, First Year After Transplant Through 2007 ($ Millions) Hepatitis B History Controversies Liver Allocation Alternatives Medical Artificial Livers Chemical-Mechanical Livers Hemotherapies Hemocleanse Bioartificial Livers Cedars-Sinai Medical Center Circe Biomedical Algenix Excorp Medical Exten Corp Organogenesis Vitagen Relative Costs Table 57 Treatment Costs For Acute Liver Failure: Transplantation And Bioartificial Liver, Us, Through 2007 ($ Millions) Figure 6 Treatment Costs For Acute Liver Failure: Transplantation And Bioartificial Liver, Us, 2000-2007 ($ Millions) Regeneration Therapy Heart Table 58 Declining Numbers In Heart Transplantation By Region Through 2007 Table 59 Us Heart Transplant Market, Through 2007 ($ Millions) Table 60 Top Four Us Heart Transplant Programs, 2000 Fewer Transplants Due To Tighter Supply Cultural Backlash Peak Year Was 1995 Waiting Lists Also Shrink Table 61 Heart Waiting List Trends, Through 2007 Are Waiting List And Transplant Numbers Inflated? Heart-Lung Numbers Table 62 Trends In Heart-Lung Transplantation By Region, Through 2007 Table 63 Us Heart-Lung Transplant Market, Through 2007 ($ Millions) Figure 7 Us Heart-Lung Transplant Market, 2000-2007 ($ Millions) Table 64 The Top Three Us Combined Heart-Lung Transplant Programs, 2000 Table 65 Heart-Lung Waiting List Trends, Through 2007 Rejection Table 66 International Heart And Lung Transplant Patient Survival Rates (%) Table 67 The Us Market For Anti-Rejection Drugs After Heart Transplantation, First Year After Transplant ($ Millions) Indications Table 68 Leading Causes Of Heart Failure (%) Tissue Typing Preservation Alternatives Medical Cholesterol Vaccine Endothelian Antagonists Animal Surgical Laser Revascularization Mitral Valve Repair Cardiac Support Devices Mechanical Thoratec World Heart Corp Micromed Vad Market Abiomed Regeneration Trumps Replacement Cellular Bioheart Lungs Table 69 Trends In Lung Transplantations By Region, Through 2007 Table 70 Us Lung Transplantation Market, Through 2007 ($ Millions) Figure 8 Us Lung Transplantation Market, 2000-2007 ($ Millions) Table 71 The Top Four Us Lung Transplant Programs, 2000 Donation Table 72 Recovered Organs Not Used, 1995-1999, Us Waiting Lists Table 73 Lung Waiting List Trends, Through 2007 Table 74 Reported Deaths On Lung Waiting List In Us, 1998-2001 Rejection Table 75 International And Us Lung Transplant And Graft Survival Rates* (%) Table 76 The Us Market For Anti-Rejection Drugs After Lung Transplantation, First Year After Transplant ($ Millions) Indications Table 77 Leading Causes Of Chronic Lung Failure, 1995-1999 (%) Preservation Celsior Hypothermosol 21 St Century Medicine History Alternatives Medical Retinoic Acid Surgical Cellular Intestines Table 78 Trends In Small Bowel Transplantation, Us, Through 2007 Table 79 Us Small Bowel Transplantation Market, Through 2007 ($ Millions) Figure 9 Us Small Bowel Transplantation Market, 2000-2007 ($ Millions) Table 80 The Top Four Us Small Bowel Transplant Programs, 2000 Poised For Growth Table 81 Countries With Small Bowel Transplant Programs Rejection Table 82 International Intestine Transplant Survival Rates (%) Types Of Transplants Table 83 Leading Causes Of Intestine Failure (%) Indications Immunosuppression Table 84 The Us Market For Anti-Rejection Drugs After Small Bowel Transplantation, First Year After Transplantation ($ Millions) Patient Follow-Up History Alternatives Medical Mechanical Cellular Tissues Eyes Cornea Table 85 Corneal Transplants In Specified Countries, 1997-2000 Table 86 Corneal Transplants And Market In The Us, Through 2007 Figure 10 Corneal Transplants And Market In The Us, 2001-2007 ($ Millions) Donors Table 87 Number Of Cornea Donors In Us Waiting List Us Other Countries Indications Tissue Testing Preservation Cryopreservation Immunosuppression History Alternatives Surgical Synthetic Retinal Degeneration Cellular Transplants Gene Therapy Electronic Implants Blood Stem Cells Numbers Table 88 Bone Marrow Transplants, Us, 1995-1999 Table 89 Projected Us Bone Marrow Transplant Procedures, Through 2007 Autologous Passes Allogenic Table 90 Worldwide Blood And Bone Marrow Transplant Patients, 1995-1998 Table 91 Projected Worldwide Blood And Bone Marrow Transplant Patients, Through 2007 Less Bone Marrow Older Patients Donors Table 92 Home Countries Of Bmdw Members Potential For Hla Testing Table 93 The Number Of Bone Marrow Donors Per 10,000 Inhab Table 93 (Continued) Waiting List Rejection Table 94 Us Market For Immunosuppressants After Blood Stem Cell Transplantation, Through 2007 ($ Millions) Indications Cell Separation Systems Immunosuppression Abgenix Biotransplant Chimeric Therapies Enzo Biochem Protein Design Labs Repligen University Of Pennsylvania History First Successful Transplant Donor Registry Established Cord Blood Alternatives Expanding Cord Blood Replicell Bones Table 95 Dominant Bone Replacement Procedures, Us, 1995-1999 Table 96 Projected Major Bone Replacement Procedures, Through 2007 Procedures Market Totals Table 97 Us And Worldwide Implant Market Growth, Through 2007 ($ Billions) Figure 11 Us And Worldwide Implant Market Growth, 2002-2007 ($ Billions) Bone Allografts Table 98 Us And World Values Of Bone Allograft Market, Through 2007 ($ Millions) Figure 12 Us And World Values Of Bone Allograft Market, 2002-2007 ($ Millions) Products Demineralized Bone Matrix Machined Implants Table 99 Us Sales Of Bone Allografts By Type, Through 2007 ($ Millions) Figure 13 Us Sales Of Bone Allografts By Type, 2000-2007 ($ Millions) Donors Mandatory Referrals Public Cynicism Donor Compensation Indications Tissue Testing Preventing Infection Preservation History Competition Alternatives Animal Bone Grafts Medical Synthetics Orthovita Exactech Spine Wave Regeneration Bone-Growth Factors Medtronic Collagen Sponges Chrysalin Bone Marrow Peripheral Blood Stem Cells Meniscus Allografts Collagen Alternative Regulation State Regulation Rules For Obtaining Consent Replacement Heart Valves, Arteries And Other Vessels Table 100 Number Of Heart Valve Transplants And Bypass Operations In The Us, 1995-1999 Heart Valve Allograft Market Table 101 Us And World Heart Valve Transplant Market, Through 2007 Tissue Valves Gain Popularity Major Competitors Vascular Grafts Table 102 Projected Number Of Heart Valve Transplants And Bypass Operations In The Us, Through 2007 Donors Valves From Morgues Public Cynicism International Trade Waiting List Indications Heart Valves Vascular Grafts Tissue Testing Preservation/Processing History Synthetics Xenografts Defects And Regulation Advances Heart Valves Vascular Grafts Alternatives Animal Heart Valves Stentless Valves Calcification Surgical Heart Valves Coronary Bypass Grafts Medical Heart Valve And Vascular Disease Mechanical/Synthetic Heart Valves Improving Blood Flow Better Maintenance Tri-Leaflet Valve Vascular Grafts Minimally Invasive Surgery Engineered Tissue Heart Valves Vascular Grafts Gene Therapy Skin, Muscle, And Matrix Table 103 Us Market Of Human Skin-Based Products, Through 2007 Skin Indications Table 104 Skin Grafts In The Us, 1995-1999 Burns Wounds Venous Ulcers Table 105 Estimated Incidence Of Venous Ulcers In The Over 64 Population, Us, Through 2007 Diabetic Ulcers Table 106 Estimated Incidence Of Diabetic Foot Ulcers, Us Pressure Ulcers Urinary Incontinence And Other Uses Table 107 Tendon, Cartilage, And Muscle Grafts, Us, 1995-1999 Cosmetic Surgery Table 108 Cosmetic Surgery Trends In The Us, 1997-2001 Table 109 Growth In Us Of Popular Cosmetic Surgeries Making Use Of Donated Human Tissue, 1999-2001 Table 110 Projected Growth In Popular Us Cosmetic Surgery Markets For Skin Products, Through 2007 (Number Of Proc Donors Public Cynicism Waiting List Rejection Tissue Testing Preservation History Alternatives Animals Biobrane Oasis Medical Repifermin Telomerase Ulcer Inspections Botox Synthetic Alloderm Integra Transcyte Dermagraft Apligraf Orcel Promogran Matrix Wound Dressing Other Uses Next Generation Products Cultured Autologous Skin Shriners Burn Hospital Other Research Regulation Cellular Transplantation Four Types Of Cells Offer Potential Numbers Donors Rejection Indications History Cancer Cells Restrictions Cellular Patents New Rule Requires Showing Of Specific And Substantial Utility Courts Join Narrowing Trend Festo Limits Doctrine Of Equivalents Ranbaxy Takes One From Glaxosmithkline Closer Look At Obviousness Crowded Race Field Alternatives Company Directory Aastrom Biosciences, Inc Abgenix Abiomed Acorn Cardiovascular, Inc Advanced Cell Technology Advanced Tissue Sciences Alexion Pharmaceutical Algenix Allosource Amgen Aortech International Apotex Corporation Usa Argus Biomedical Pty Ariad Pharmaceuticals Arrow International Ats Medical Inc Avant Immunotherapeutics Avax Technologies Aventis Pharma Us Barr Laboratories Bausch & Lomb Baxter International Inc Bertek Pharmaceutical Bio Array Solutions Bioheart, Inc Biohybrid Technologies Biolife Technologies, Inc Biotest Diagnostics Corp Biotransplant Biotronik, Inc Cardiogenesis Cardion Pharmaceuticals, Inc Cardiowest Technologies Chimeric Therapies Chrysalis Biotechnology Circe Biomedical, Inc Cook Biotechnology Corixa Corp Cr Bard Cryolife Curis Depuy Acromed, Inc Diacrin Digene Dynal Biotech Edwards Life Sciences Enzo Biochem Enzon Eon Labs, Inc Exactech, Inc Excorp Exten Industries Fujisawa Healthcare, Inc Genentech Genovision Genzyme Genzyme Transgenics Corp Geron Corp Gti, Inc Guidant Hemocleanse Hemotherapies Incara Pharmaceuticals Infigen Immerge Biotherapeutics Ilex Oncology Immucor Immunex Innogenetics, Inc Integra Life Sciences Interpore Cross International Isis Pharmaceuticals, Inc Islet Technologies Isotis Kriton Medical L-Vad Technology, Inc Layton Bioscience Lifecell Corp Lifenet Mast Diagnostic Medimmune Medtronic Merck & Co, Inc Micromed Technology Inc Muskuloskeletal Transplant Foundation (Mtf) National Genetics Institute Nextran Nippon Kayaku Co Novamont Nuerochem Inc Novartis Pharmaceutical Odyssey Pharmaceuticals, Inc One Lambda Orchid Biosciences Organogenesis Orquest, Inc Ortec International, Inc Ortho Biotech Products, Lp Orthologic Corp Orthovita Paradigm Genetics Pel-Freez Clinical Systems, Llc Pharmacia Corporation Ppl Therapeutics Plc Prometheus Laboratories Inc Protein Design Labs Protein Polymer Technologies, Inc Pyrosequencing Ab Quest Diagnostics Questcor Pharmaceuticals, Inc Regen Biologics Regeneration Technologies Repligen Robbins Scientific Roche (F Hoffmann-La Roche Ltd) Roxane Laboratories, Inc St Jude Medical Sangstat Select Therapeutics Sidmak Snia Group Spinal Concepts, Inc Spine Wave, Inc Stem Cells, Inc Stem Cell Technologies Styker Corporation Sulzer Carbomedics Sulzer Orthopedics Sulzer Spine-Tech Tanox Thoratec Tutogen Medical, Inc Twenty-First Century Medicine Vitagen Waters Medical Systems World Heart Corp Wyeth (Formerly American Home Products) List Of Tables Summary Table: Us Organ And Tissue Transplantation Markets, Through 2007 Table 1 Us Organ Transplants, Average 1 St Year Cost And Market Totals, Through 2007 Table 2 Numbers Of Donated Cadavers By Region, 1997-2001 Table 3 Tissue Grafting In The Us, Through 2007 (Number Of Procedures) Table 4 Potential And Expected Us Markets For Transplanted Human Tissue, Through 2007 ($ Millions) Table 5 Recovered Organs Not Used, 1995-1999 Table 6 Consented Organs Not Recovered, 1995-1999 Table 7 Major Organ Preservation Solutions Table 8 The North American And World Markets For Organ Preservation Solution (Except Papwork Cocktail), Through 2007 Table 9 Types Of Typing Table 10 Players In The Hla Typing Market Table 11 The Us Market For Tissue Typing Services, Through 2007 ($ Millions) Table 12 Number Of Patients In The Us Who Are On Waiting List Because Of Graft Failure (Failure Of Previously Transplanted Organ), All Organs, 1995-1999 Table 13 Percent Of Us Patients On Waiting List By Organ Who Had A Previous Transplant, 1995-1999 (%) Table 14 Us Organ Recipients Who Previously Had A Transplant, All Organs, 1995-1999 Table 15 Worldwide Market For Immunosuppression, Through 2007 Table 16 Worldwide Sales Of Immunosuppressives By Company, 1999-2001 ($ Millions) Table 17 Us Sales Of Immunosuppressives By Type, Through 2007* ($ Millions) Table 18 World Sales Of Immunosuppressive By Type, Through 2007 ($ Millions) Table 19 Experimental Immunosuppressives By Type Table 20 Common Post-Transplant Infections Table 21 Common Post-Transplant Drugs Table 22 Cost Of Transplant Antibiotics In The Us, Through 2007 ($ Millions) Table 23 The World Market For Transplant Drug And Disease Monitoring Agents, Through 2007 ($ Millions) Table 24 Maximum Potential For Additional Organs Compared To Demand In The Us, 1999 Table 25 International Organ Donor Rates, 2000 (Per Million Of Population) Table 26 Transplantations And Waiting List Numbers In Spain, 2000 Table 27 Selected Countries And Type Of Consent Table 28 Countries With Kidney Transplant Programs Table 29 Kidney, Liver, Heart Transplants By Region, 2000 Table 30 Trends In Living And Cadaveric Donation In The Us, Through 2007 Table 31 Growth Of Selected Population Groups In The Us, Through 2007 (Millions) Table 32 Number Of Kidney Transplantations By Region, Through 2007 Table 33 The Us Kidney Transplant Market, Through 2007 ($ Millions) Table 34 The Top Four Kidney Transplant Programs In The Us, 2000 (By Number Of Procedures) Table 35 Kidney Patient And Graft Survival, Us (%) Table 36 Costs Per Year Due To End Stage Renal Disease, 1995-1999 Table 37 Waiting List Trends By Region, Through 2007 Table 38 Number Of Kidney Transplantations In The Us From Living And Cadaveric Donors, Through 2007 Table 39 Kidney Transplantation In Norway From Living And Cadaveric Donors, Through 2007 Table 40 Leading Causes Of Kidney Failure (%) Table 41 Leading Causes Of Kidney Transplantation (%) Table 42 Hazard Ratio For Graft Failure (1993=1) Table 43 Estimated Us Market For Immunosuppressives For Kidney Transplant Patients, Through 2007 Table 44 Growth Of Whole Pancreas Transplantation, Through 2007 Table 45 Us Whole Pancreas Transplantation Market, Through 2007 ($ Millions) Table 46 The Top Four Pancreas Transplant Programs In The Us, 2000 (Number Of Transplants) Table 47 International And Us Pancreas Graft Survival Rates (%) Table 48 Pancreas Waiting List, Us, Through 2007 Table 49 Growth In Liver Transplants By Region, Through 2007 Table 50 Liver Transplant Market In The Us, Through 2007 ($ Millions) Table 51 The Top Four Liver Transplant Programs In The Us, 2000 Table 52 Trends In Living Donor Liver Transplants In The Us Table 53 Growth In Liver Waiting Lists By Region, Through 2007 Table 54 Deaths On Liver Waiting List, Us, Through 2007 Table 55 Liver Transplant Survival Rates* (%) Table 56 The Us Market For Immunosuppressants After Liver Transplantation, First Year After Transplant Through 2007 ($ Millions) Table 57 Treatment Costs For Acute Liver Failure: Transplantation And Bioartificial Liver, Us, Through 2007 ($ Millions) Table 58 Declining Numbers In Heart Transplantation By Region, Through 2007 Table 59 Us Heart Transplant Market, Through 2007 ($ Millions) Table 60 Top Four Us Heart Transplant Programs, 2000 Table 61 Heart Waiting List Trends, Through 2007 Table 62 Trends In Heart-Lung Transplantation By Region, Through 2007 Table 63 Us Heart-Lung Transplant Market, Through 2007 ($ Millions) Table 64 The Top Three Us Combined Heart-Lung Transplant Programs, 2000 Table 65 Heart-Lung Waiting List Trends, Through 2007 Table 66 International Heart And Lung Transplant Patient Survival Rates (%) Table 67 The Us Market For Anti-Rejection Drugs After Heart Transplantation, First Year After Transplant ($ Millions) Table 68 Leading Causes Of Heart Failure (%) Table 69 Trends In Lung Transplantations By Region, Through 2007 Table 70 Us Lung Transplantation Market, Through 2007 ($ Millions) Table 71 The Top Four Us Lung Transplant Programs, 2000 Table 72 Recovered Organs Not Used, 1995-1999, Us Table 73 Lung Waiting List Trends, Through 2007 Table 74 Reported Deaths On Lung Waiting List In Us, 1998-2001 Table 75 International And Us Lung Transplant And Graft Survival Rates* (%) Table 76 The Us Market For Anti-Rejection Drugs After Lung Transplantation, First Year After Transplant ($ Millions) Table 77 Leading Causes Of Chronic Lung Failure, 1995-1999 (%) Table 78 Trends In Small Bowel Transplantation, Us, Through 2007 Table 79 Us Small Bowel Transplantation Market, Through 2007 ($ Millions) Table 80 The Top Four Us Small Bowel Transplant Programs, 2000 Table 81 Countries With Small Bowel Transplant Programs Table 82 International Intestine Transplant Survival Rates (%) Table 83 Leading Causes Of Intestine Failure (%) Table 84 The Us Market For Anti-Rejection Drugs After Small Bowel Transplantation, First Year After Transplantation ($ Millions) Table 85 Corneal Transplants In Specified Countries, 1997-2000 Table 86 Corneal Transplants And Market In The Us, Through 2007 Table 87 Number Of Cornea Donors In Us Table 88 Bone Marrow Transplants, Us, 1995-1999 Table 89 Projected Us Bone Marrow Transplant Procedures, Through 2007 Table 90 Worldwide Blood And Bone Marrow Transplant Patients, 1995-1998 Table 91 Projected Worldwide Blood And Bone Marrow Transplant Patients, Through 2007 Table 92 Home Countries Of Bmdw Members Table 93 The Number Of Bone Marrow Donors Per 10,000 Inhabitants Table 94 Us Market For Immunosuppressants After Blood Stem Cell Transplantation, Through 2007 ($ Millions) Table 95 Dominant Bone Replacement Procedures, Us, 1995-1999 Table 96 Projected Major Bone Replacement Procedures, Us, Through 2007 Table 97 Us And Workdwide Implant Market Growth, Through 2007 ($ Billions) Table 98 Us And World Values Of Bone Allograft Market, Through 2007 ($ Millions) Table 99 Us Sales Of Bone Allografts By Type, Through 2007 ($ Millions) Table 100 Number Of Heart Valve Transplants And Bypass Operations In The Us, 1995-1999 Table 101 Us And World Heart Valve Transplant Market, Through 2007 Table 102 Projected Number Of Heart Valve Transplants And Bypass Operations In The Us, Through 2007 Table 103 Us Market Of Human Skin-Based Products, Through 2007 Table 104 Skin Grafts In The Us, 1995-1999 Table 105 Estimated Incidence Of Venous Ulcers In The Over 64 Population, Us, Through 2007 Table 106 Estimated Incidence Of Diabetic Foot Ulcers, Us Table 107 Tendon, Cartilage, And Muscle Grafts, Us, 1995-1999 Table 108 Cosmetic Surgery Trends In The Us, 1997-2001 Table 109 Growth In Us Of Popular Cosmetic Surgeries Making Use Of Donated Human Tissue, 1999-2001 Table 110 Projected Growth In Popular Us Cosmetic Surgery Markets For Skin Products, Through 2007 (Number Of Procedures) List of Figures Summary Figure: Us Organ And Tissue Transplantation Markets, 2002 And 2007 ($ Millions) Figure 1 Issue Grafting In The Us, 2002 - 2007 (Number Of Procedures) Figure 2 Us Sales Of Immunosuppressives By Type, 1999-2007 ($ Millions) Figure 3 The Us Kidney Transplant Market, 2002-2007 ($ Millions) Figure 4 Us Whole Pancreas Transplantation Market, 2000-2007 ($ Millions) Figure 5 Liver Transplant Market In The Us, 2000-2007 ($ Millions) Figure 6 Treatment Costs For Acute Liver Failure: Transplantation And Bioartificial Liver, Us, 2000-2007 ($ Millions) Figure 7 Us Heart-Lung Transplant Market, 2000-2007 ($ Millions) Figure 8 Us Lung Transplantation Market, 2000-2007 ($ Millions) Figure 9 Us Small Bowel Transplantation Market, 2000-2007 ($ Millions) Figure 10 Corneal Transplants And Market In The Us, 2001-2007 ($ Millions) Figure 11 Us And Worldwide Implant Market Growth, 2002-2007 ($ Billions) Figure 12 Us And World Values Of Bone Allograft Market, 2002-2007 ($ Millions) Figure 13 Us Sales Of Bone Allografts By Type, 2000-2007 ($ Millions) AbstractThe rapidly growing tissue and organ transplantation market, which recently topped 1 million procedures in a year, worldwide, is on the cusp of even more dramatic changes. While some sectors, such as bone and tissue grafts, are on a trajectory of rapid growth, others, such as heart transplants, are poised for sharp decline. This in-depth study analyses market opportunities and trends in the development and regulation of specialized products used in preparation for transplantation, directly in transplantation procedures, in patient recovery from such procedures, and in graft maintenance. The report includes evaluations of health care trends and advances in non-transplant therapies that will affect the transplantation market, and it also provides forecasts for the period 2002 through 2007.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||